Among diverse regulatory effects, CTRP3 has recently been reported to affect adipose tissue mass and obesity [13,14,15]; to exert protective effects on metabolic dysregulations, such as hepatic steatosis and insulin resistance [16,17]; and to exhibit anti-inflammatory properties in diverse pathophysiological contexts [18,19]. Here, C1QTNF3 is linked to obesity disorder.